Clinical Trial Update: Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates [NA]

View source ↗

Summary

This document reports a terminated neoadjuvant trial of gefitinib (IRESSA) as a single-agent preoperative therapy for non-small cell lung cancer, with molecular…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Lung Cancer | NA | Status: TERMINATED | Results posted: 2012-10-31